Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (369 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-06-23. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: subjectssubjectplacebodouble blindday
  Phrases that lowered it: cellevaluatelimitanticells
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past trials: 2203 (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Sponsor's past termination rate: 5.9% (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Number of arms: 4 (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports with a death: 21.8% (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Disease area, dermatology: Yes (raises risk) · Disease area
• Disease area, cancer: No (lowers risk) · Disease area
• Blinding: double (raises risk) · Design
• Drug's FAERS reports marked serious: 91.2% (raises risk) · Drug's FDA history
• Drug's FAERS reports before start: 40103 (lowers risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Maximum age: not given (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE NCT03312907 · started 2018 · scored riskier than 80% of active trials completed
• Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus NCT02880852 · started 2017 · scored riskier than 28% of active trials completed
• Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome NCT02067910 · started 2014 · scored riskier than 46% of active trials completed
• The Evaluation of Belimumab in Myasthenia Gravis (MG) NCT01480596 · started 2013 · scored riskier than 23% of active trials completed
• A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus Erythematosus NCT05140824 · started 2021 · scored riskier than 47% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.